Drug Trial Radar · NCT04856917
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
Last checked: Nov 20, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
123
Actual
Start
May 15, 2021
Primary completion
Feb 1, 2022
Study completion Mar 29, 2022
Sponsor
- Lead sponsor
- Vanda PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Apr 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Efficacy and Safety of Imsidolimab in Participants with Acne Vulgaris
Conditions
- Acne Vulgaris
Interventions
ImsidolimabDrug
Humanized Monoclonal Antibody
PlaceboBiological
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Facial Inflammatory Lesion Counts at Week 12Time frame: Baseline, Week 12
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
Site 10-114
Hot Springs, Arkansas
Site 10-111
Fountain Valley, California
Site 10-106
Sherman Oaks, California
Site 10-113
Sweetwater, Florida
Site 10-108
Tampa, Florida
Site 10-107
Tampa, Florida
Site 10-109
New Orleans, Louisiana
Site 10-112
New Orleans, Louisiana
Site 10-104
Detroit, Michigan
Site 10-110
Portsmouth, New Hampshire
Site 10-105
Murfreesboro, Tennessee
Site 10-103
Austin, Texas
Site 10-102
College Station, Texas
Site 10-101
San Antonio, Texas
Site 10-115
Waterloo, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.